Previous close | 168.57 |
Open | 169.00 |
Bid | 167.66 x 800 |
Ask | 169.91 x 1100 |
Day's range | 167.79 - 170.34 |
52-week range | 130.96 - 182.89 |
Volume | |
Avg. volume | 5,693,979 |
Market cap | 299.174B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | 50.57 |
EPS (TTM) | 3.35 |
Earnings date | 25 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | 6.20 (3.66%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | 183.88 |
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since AbbVie Inc. (NYSE:ABBV) is part of our list, we have analyzed the stock in detail. The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently […]